It's kinda suspicious that a group of billionaires are spending 10s of millions of dollars trying to unseat a single Republican Congressman from Kentucky who just happens to be one of the few members of Congress that refuses to be a puppet of a foreign nation.
9 of every 10 new American jobs since pre-COVID went to someone born outside the country.
Triple checked the data. It's real.
+4.3M foreign-born.
+471K native-born.
Meanwhile, 335,000+ American layoffs in 2026.
HOW DO WE ALLOW THIS?
The legal system has a specific way of handling health care fraud: if you are a nursing assistant in Florida, you get nine years in federal prison for an $11 million scheme. If you are a multibillion-dollar pharmacy conglomerate, you pay a fine and continue business as usual.
The disparity in accountability is staggering. While individual practitioners face the full weight of the law for fraudulent billing, CVS Health and its subsidiaries have spent the last several years settling allegation after allegation involving hundreds of millions of dollars in taxpayer and patient funds.
The $615 Million Overcharge
The most recent and egregious example involves a March 2026 federal audit of the Federal Employees Health Benefits Program. Investigators found that CVS Caremark overcharged the program by $615 million between 2018 and 2021. The scheme involved failing to pass through negotiated discounts and credits, essentially pocketing money that was contractually required to be returned to the health plan.
The Offshore Rebate Shell Game
CVS has also been accused of using an offshore shell company called Zinc Health Services to hide billions in rebates. By funneling manufacturer payments through this entity—which operates with a skeleton staff—CVS allegedly bypassed contractual obligations to share those rebates with health plan clients and patients. This practice effectively artificially inflated drug prices for the end consumer while padding corporate profits.
A Timeline of Settlements and Accusations
The record of corporate misconduct extends across every facet of the CVS business model, from Medicare Advantage to retail pharmacy operations:
March 2026: Aetna, a CVS subsidiary, agreed to pay $118 million to resolve allegations of "upcoding" members' health risks to inflate Medicare Advantage reimbursements.
December 2025: CVS settled whistleblower allegations for $37.7 million regarding the overbilling of government programs for insulin. The company reportedly recorded 50-day supplies as 30-day supplies to trigger premature refills.
October 2025: The company paid $18.2 million to settle claims that it submitted false certifications to Medi-Cal for medications that were not medically necessary or supported by documentation.
June 2024: Illinois reached a $45 million settlement with CVS Caremark over the failure to disclose the true nature of the Zinc rebate scheme.
2022: CVS agreed to a massive $5 billion settlement with multiple states to resolve claims regarding its role in the opioid epidemic and the failure to monitor suspicious prescriptions.
The math of the American justice system is clear. For the individual, fraud is a life-altering criminal sentence. For the corporation, it is simply a line item on a balance sheet—the cost of doing business. When the "days without fraud" whiteboard hits zero, the only thing that changes is the size of the next settlement check.